Given its pioneering pharmacological features, along with its proven positive benefit-risk profile, and the relevant epidemiological context, icodec is expected to significantly impact diabetes management, especially in T2DM insulin-naïve patients, ensuring healthcare professionals have a new reliable and efficient therapeutic option for those patients needing an insulin treatment. Here, INS is linked to type 2 diabetes mellitus.